feedback

Course Director

Sara M. Tinsley, PhD, ARNP, AOCN
Sara M. Tinsley, PhD, ARNP, AOCN

Moffitt Cancer Center
Tampa, Florida

Faculty

Jean A. Ridgeway
Jean A. Ridgeway, DNP, APN, NP-C, AOCN

University of Chicago Medicine
Chicago, Illinois

Ilene Galinsky
Ilene Galinsky, BSN, MSN, ANP-C

Dana Farber Cancer Institute
Boston, Massachusetts

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CE
Credit Amount:1.5 Credits
Release Date:2016-May-31
Expiration Date:2017-May-30
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

Oncology nurse professionals play a key role in the management of patients with myeloproliferative neoplasms (MPNs), including diseases such as myelofibrosis (MF) and polycythemia vera (PV). Recent years have seen the emergence of new thinking on disease biology, updated diagnostic protocols, and novel agent classes that can be used to manage MPN symptoms and improve patient outcomes; all of these developments have implications for nursing care and the role of the nurse in MPN management.

This activity which is based on a recent live symposium, will offer oncology nurse professionals insight from their expert colleagues on the current risk-adapted approach to managing MPNs, the role of new agent classes such as JAK inhibitors, and recommendations on how to use effective strategies to educate patients on the nature and clinical burden of diseases such as MF or PV.

Upon completion of this activity, participants will be able to:
  • Identify the clinical signs and symptoms associated with myeloproliferative neoplasms (MPNs), such as myelofibrosis (MF) and polycythemia vera (PV)
  • Educate patients and caregivers on the potential complications associated with uncontrolled symptoms of MPNs, such as PV and MF
  • Explain the risks and benefits of conventional and novel therapy for MPNs, including JAK inhibitors, across multiple clinical settings
  • Communicate with MPN patients and caregivers in order to explain clinical decision-making or customize a treatment plan or schedule
  • Manage safety issues in patients with MF or PV who are receiving novel therapy as part of their treatment

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, advanced practice oncology nurses, nurse practitioners, and other healthcare professionals involved in the care of patients with MPNs.

Nursing Education Purpose Statement

The purpose of this activity is to improve the knowledge and competence of nurses concerning the treatment of MPNs.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 31, 2016 - May 30, 2017
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity for any amount during the past 12 months.

Course Director and Moderator

Sara M. Tinsley, PhD, ARNP, AOCN
Nurse Practitioner, Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Sara M. Tinsley, PhD, ARNP, AOCN, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with ARIAD Pharmaceuticals, Inc.; Celgene Corporation; Incyte Corporation; and Novartis Pharmaceuticals Corporation.
Advisory Board for Gilead; Onyx Pharmaceuticals/Amgen Inc.; and Teva Pharmaceuticals USA.
Sara M. Tinsley, PhD, ARNP, AOCN, does intend to discuss either non−FDA-approved or investigational use for the following products/devices: a number of therapeutic options for myelofibrosis, polycythemia vera, and other myeloproliferative neoplasms.‚Äč

Faculty

Jean A. Ridgeway, DNP, APN, NP-C, AOCN
Lead Advance Practice Provider-Adult Stem Cell Transplantation
University of Chicago Medicine
Chicago, Illinois

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Amgen Inc.; Celgene Corporation; Genentech, Inc.; and Pharmacyclics.
Jean A. Ridgeway, DNP, APN, NP-C, AOCN, does intend to discuss either non−FDA-approved or investigational use for the following products/devices: a number of therapeutic options for myelofibrosis and other myeloproliferative neoplasms.

Ilene Galinsky, BSN, MSN, ANP-C
Senior Program Research Nurse Practitioner Adult Leukemia Program
Dana Farber Cancer Institute
Boston, Massachusetts

Ilene Galinsky, BSN, MSN, ANP-C, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Pfizer Inc.
Ilene Galinsky, BSN, MSN, ANP-C, does intend to discuss either non−FDA-approved or investigational use for the following products/devices: a number of therapeutic options for polycythemia vera and other myeloproliferative neoplasms.

Nurse Reviewer

Suzanne M. Costello, RN, MSN, AOCNS
BMT Program Manager
Columbia University Medical Center
New York, New York

Suzanne M. Costello, RN, MSN, AOCNS, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hour(s).

Providership

This CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Incyte Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2016, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.